Overview
- This week a Brazilian team published a case report describing an anonymized woman in her 80s with advanced dementia who received a supervised 5‑gram oral dose of psilocybin‑containing mushrooms and a second 3‑gram dose a month later.
- Researchers reported rapid, multi‑domain improvements after the first session including clearer speech, restored urinary continence, independent dressing and walking, and increased social and emotional engagement that persisted for weeks.
- Acute reactions after the first dose included heavy sweating, high temperature and a prolonged sleep‑like state, and the authors reported no other severe or lasting adverse effects in this single case.
- The report has major limits because it is a single uncontrolled observation with no standardized cognitive tests, no brain imaging or electrophysiological monitoring, and no biomarker confirmation of Alzheimer’s pathology.
- Authors and outside experts say the finding is hypothesis‑generating and call for carefully controlled trials to define safe dosing, test efficacy, and examine mechanisms within the broader, evolving field of psilocybin research.